{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:06:42Z","timestamp":1789031202991,"version":"build-2803163510"},"reference-count":62,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NMRC Centre Grant Programme -Targeted Therapy for Blood Cancer","award":["NMRC\/CG\/C012A\/2017"],"award-info":[{"award-number":["NMRC\/CG\/C012A\/2017"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by extensive heterogeneity in genetics, response to therapy and long-term outcomes, making it a prototype example of development for personalized medicine. Given the accessibility to hematologic malignancy patient samples and recent advances in high-throughput technologies, large amounts of biological data that are clinically relevant for diagnosis, risk stratification and targeted drug development have been generated. Recent studies highlight the potential of implementing genomic-based and phenotypic-based screens in clinics to improve survival in patients with refractory AML. In this review, we will discuss successful applications as well as challenges of most up-to-date high-throughput technologies, including artificial intelligence (AI) approaches, in the development of personalized medicine for AML, and recent clinical studies for evaluating the utility of integrating genomics-guided and drug sensitivity testing-guided treatment approaches for AML patients.<\/jats:p>","DOI":"10.3390\/ijms23052863","type":"journal-article","created":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T20:38:16Z","timestamp":1646599096000},"page":"2863","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress"],"prefix":"10.3390","volume":"23","author":[{"given":"Wei","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Haematology, Singapore General Hospital, Singapore 169608, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Hui","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Haematology, Singapore General Hospital, Singapore 169608, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giridharan","family":"Periyasamy","sequence":"additional","affiliation":[{"name":"High Throughput Phenomics Platform, Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), Singapore 139632, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Chuah","sequence":"additional","affiliation":[{"name":"Department of Haematology, Singapore General Hospital, Singapore 169608, Singapore"},{"name":"Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore 169857, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/asheducation-2011.1.43","article-title":"Novel approaches to the treatment of acute myeloid leukemia","volume":"2011","author":"Roboz","year":"2011","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/asheducation-2011.1.36","article-title":"Impact of genetic features on treatment decisions in AML","volume":"2011","author":"Dohner","year":"2011","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.5045\/br.2020.S003","article-title":"New agents in acute myeloid leukemia (AML)","volume":"55","author":"Park","year":"2020","journal-title":"Blood Res"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: Prognostic and therapeutic implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"37790","DOI":"10.18632\/oncotarget.26492","article-title":"Precision medicine in the treatment stratification of AML patients: Challenges and progress","volume":"9","author":"Lohse","year":"2018","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1126\/science.aaz3023","article-title":"Artificial intelligence in cancer therapy","volume":"367","author":"Ho","year":"2020","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1126\/science.1183424","article-title":"Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML","volume":"328","author":"Zhang","year":"2010","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhou, G.B., Zhao, W.L., Wang, Z.Y., Chen, S.J., and Chen, Z. (2005). Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020012"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2003-06-1969","article-title":"FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8817","DOI":"10.2147\/CMAR.S177894","article-title":"Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection","volume":"11","author":"Abbas","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12967-017-1281-x","article-title":"Molecular targeting in acute myeloid leukemia","volume":"15","author":"Lim","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-07-604512","article-title":"Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia","volume":"127","author":"Wouters","year":"2016","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1053\/j.seminoncol.2008.04.008","article-title":"Epigenetics in acute myeloid leukemia","volume":"35","author":"Plass","year":"2008","journal-title":"Semin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pleyer, L., Dohner, H., Dombret, H., Seymour, J.F., Schuh, A.C., Beach, C.L., Swern, A.S., Burgstaller, S., Stauder, R., and Girschikofsky, M. (2017). Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020415"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ajh.24782","article-title":"Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia","volume":"92","author":"Ragon","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.13016","article-title":"A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome","volume":"167","author":"Kirschbaum","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2013.347","article-title":"Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib","volume":"28","author":"Schaab","year":"2014","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.leukres.2011.01.010","article-title":"DIGE-based proteomic analysis identifies nucleophosmin\/B23 and nucleolin C23 as over-expressed proteins in relapsed\/refractory acute leukemia","volume":"35","author":"Hu","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jprot.2011.02.034","article-title":"Identification of prognostic protein biomarkers in childhood acute lymphoblastic leukemia (ALL)","volume":"74","author":"Jiang","year":"2011","journal-title":"J Proteomics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1074\/mcp.M112.017483","article-title":"Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance","volume":"11","author":"Alcolea","year":"2012","journal-title":"Mol. Cell. Proteom. MCP"},{"key":"ref_30","first-page":"1758","article-title":"The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics","volume":"5","author":"Kornblau","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 inhibition in AML: An unexpected bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax Combined with Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib\/II Study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.2217\/fon-2019-0373","article-title":"Glasdegib plus intensive\/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials","volume":"15","author":"Cortes","year":"2019","journal-title":"Future Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/14789450.2018.1487781","article-title":"Shining a light on cell signaling in leukemia through proteomics: Relevance for the clinic","volume":"15","author":"Hoff","year":"2018","journal-title":"Expert Rev. Proteom."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100647","DOI":"10.1016\/j.jbior.2019.100647","article-title":"Multi-omic approaches to improve outcome for T-cell acute lymphoblastic leukemia patients","volume":"74","author":"Cordo","year":"2019","journal-title":"Adv. Biol. Regul."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","article-title":"Targeting Metabolism for Cancer Therapy","volume":"24","author":"Luengo","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood-2014-02-554204","article-title":"A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2016.08.057","article-title":"Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia","volume":"167","author":"Sykes","year":"2016","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Loew, A., Kohnke, T., Rehbeil, E., Pietzner, A., and Weylandt, K.H. (2019). A Role for Lipid Mediators in Acute Myeloid Leukemia. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102425"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ymgme.2020.05.005","article-title":"Metabolomics in acute myeloid leukemia","volume":"130","author":"Wojcicki","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Stevens, V.L., Hoover, E., Wang, Y., and Zanetti, K.A. (2019). Pre-Analytical Factors that Affect Metabolite Stability in Human Urine, Plasma, and Serum: A Review. Metabolites, 9.","DOI":"10.3390\/metabo9080156"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41467-017-00451-5","article-title":"Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time","volume":"8","author":"Chia","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2017.11.008","article-title":"Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study","volume":"64","author":"Swords","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/s41467-019-09917-0","article-title":"A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML","volume":"10","author":"Drenberg","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mc.23163","article-title":"Identification of a synergistic combination of dimethylaminoparthenolide and shikonin alters metabolism and inhibits proliferation of pediatric precursor-B cell acute lymphoblastic leukemia","volume":"59","author":"Sweeney","year":"2020","journal-title":"Mol. Carcinog."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"E7554","DOI":"10.1073\/pnas.1703094114","article-title":"Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies","volume":"114","author":"Kurtz","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/bloodadvances.2020001934","article-title":"Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms","volume":"4","author":"Spinner","year":"2020","journal-title":"Blood Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.drudis.2017.09.005","article-title":"High-throughput flow cytometry for drug discovery: Principles, applications, and case studies","volume":"22","author":"Ding","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1021\/acsmedchemlett.6b00316","article-title":"Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia","volume":"7","author":"Lewis","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1093\/bioinformatics\/btv427","article-title":"Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data","volume":"31","author":"Ryall","year":"2015","journal-title":"Bioinformatics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/svn-2019-000290","article-title":"Artificial intelligence and big data facilitated targeted drug discovery","volume":"4","author":"Liu","year":"2019","journal-title":"Stroke Vasc. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Menden, M.P., Iorio, F., Garnett, M., McDermott, U., Benes, C.H., Ballester, P.J., and Saez-Rodriguez, J. (2013). Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061318"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"eaan0941","DOI":"10.1126\/scitranslmed.aan0941","article-title":"Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)","volume":"10","author":"Rashid","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-020-0276-7","article-title":"Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma","volume":"10","author":"Rashid","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/2472630319890316","article-title":"CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence","volume":"25","author":"Blasiak","year":"2020","journal-title":"SLAS Technol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"333ra49","DOI":"10.1126\/scitranslmed.aac5954","article-title":"Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform","volume":"8","author":"Zarrinpar","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1800104","DOI":"10.1002\/adtp.201800104","article-title":"Modulating BET Bromodomain inhibitor ZEN-3694 and enzalutamide combination dosing in a metastatic prostate cancer patient using CURATE. AI, an artificial intelligence platform","volume":"1","author":"Pantuck","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.drudis.2015.05.013","article-title":"The right drugs at the right time for the right patient: The MD Anderson precision oncology decision support platform","volume":"20","author":"Johnson","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","article-title":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: Feasibility and preliminary efficacy of the Beat AML Master Trial","volume":"26","author":"Burd","year":"2020","journal-title":"Nat. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/5\/2863\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:32:45Z","timestamp":1760135565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/5\/2863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,5]]},"references-count":62,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ijms23052863"],"URL":"https:\/\/doi.org\/10.3390\/ijms23052863","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,5]]}}}